Cargando…

Diflunisal in late-onset FAP patients with moderate to severe neuropathy

Detalles Bibliográficos
Autores principales:	Obici, Laura, Cortese, Andrea, Perlini, Stefano, Lozza, Alessandro, Casarini, Simona, Alfonsi, Enrico, Merlini, Giampaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641996/ http://dx.doi.org/10.1186/1750-1172-10-S1-O24

Ejemplares similares

Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study
por: Cortese, Andrea, et al.
Publicado: (2015)

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

Diflunisal compassive use in transthyretin familial amyloidotic polyneuropathy (TTR-FAP): report of the first Spanish experience
por: Contesse, Sebastián E Azorín, et al.
Publicado: (2015)

Unravelling the epidemiology of late-onset and asymptomatic carriers of FAP ATTR V30M in a Portuguese population
por: Lemos, Carolina, et al.
Publicado: (2015)

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy
por: Nedkova-Hristova, Velina, et al.
Publicado: (2022)

Cooperative Stabilization of Transthyretin by Clusterin and Diflunisal
por: Greene, Michael J., et al.
Publicado: (2014)

Diflunisal inhibits prestin by chloride-dependent mechanism
por: Duret, Guillaume, et al.
Publicado: (2017)

Diflunisal Targeted Delivery Systems: A Review
por: Snetkov, Petr, et al.
Publicado: (2021)

Neurophysiological pitfalls in TTR-FAP Val30Met
por: Conceição, Isabel, et al.
Publicado: (2015)

Mutation-negative FAP patients with mRNA defects of APC
por: Condie, Michelle W, et al.
Publicado: (2010)

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
por: Vegezzi, Elisa, et al.
Publicado: (2022)

Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models
por: Cardoso, Isabel, et al.
Publicado: (2010)

Specific ophtalmologic changes in late onset familial amyloid polyneuropathy (FAP) portuguese patients
por: Ferreira, Natalia, et al.
Publicado: (2015)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

TTR-FAP: a single-center experience in Sicily, an Italian endemic area
por: Mazzeo, Anna, et al.
Publicado: (2015)

The hidden story behind gender differences in familial amyloid polyneuropathy (FAP) ATTRV30M
por: Santos, Diana, et al.
Publicado: (2015)

Diflunisal Attenuates Virulence Factor Gene Regulation and Phenotypes in Staphylococcus aureus
por: Chan, Liana C., et al.
Publicado: (2023)

Diflunisal and Analogue Pharmacophores Mediating Suppression of Virulence Phenotypes in Staphylococcus aureus
por: Chan, Liana C., et al.
Publicado: (2023)

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP
por: Parman, Yesim, et al.
Publicado: (2016)

Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
por: Shirakawa, Kotaro, et al.
Publicado: (2016)

Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors
por: Coşkun, Göknil Pelin, et al.
Publicado: (2018)

Effect of Hydrophilic Polymers on Complexation Efficiency of Cyclodextrins in Enhancing Solubility and Release of Diflunisal
por: Bashir, Mehreen, et al.
Publicado: (2020)

Osteosarcoma Stem Cell Potent Gallium(III)‐Polypyridyl Complexes Bearing Diflunisal
por: Xiao, Zhiyin, et al.
Publicado: (2021)

Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: a comparison between late- and early-onset disease
por: Raya-Cruz, Manuel, et al.
Publicado: (2015)

Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area
por: Cortese, Andrea, et al.
Publicado: (2015)

Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)
por: Adams, David, et al.
Publicado: (2015)

Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
por: Schoser, Benedikt
Publicado: (2013)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan
por: Miyake, Zenshi, et al.
Publicado: (2018)

Ketoprofeno vs diflunisal por vía oral para analgesia postoperatoria posterior a anestesia regional
por: Montalvo Cuevas, Silvanya
Publicado: (1998)

Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells
por: Renner, Kathrin, et al.
Publicado: (2018)

Diflunisal‐loaded poly(propylene sulfide) nanoparticles decrease S. aureus‐mediated bone destruction during osteomyelitis
por: Ford, Caleb A., et al.
Publicado: (2020)

Nanoemulgel, an Innovative Carrier for Diflunisal Topical Delivery with Profound Anti-Inflammatory Effect: in vitro and in vivo Evaluation
por: Bashir, Mehreen, et al.
Publicado: (2021)

Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations
por: Gomaraschi, Monica, et al.
Publicado: (2011)

A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli
por: Rognoni, Paola, et al.
Publicado: (2013)

181. Potential Benefit of Masking and other COVID-19 Infection Prevention Measures on Late-Onset Infections in the NICU
por: Bultmann, Charlene, et al.
Publicado: (2021)

Validated Stability-Indicating HPLC-DAD Method for the Simultaneous Determination of Diclofenac Sodium and Diflunisal in Their Combined Dosage Form
por: Shaalan, Rasha A., et al.
Publicado: (2013)

Decreased exercise capacity in ‘asymptomatic’ patients late after relief of severe pulmonary stenosis and moderate restenosis: evidence for diastolic dysfunction
por: Romeih, Soha, et al.
Publicado: (2012)

Nasal polyps, aspirin sensitivity, and late onset asthma are crucial to identify severe asthma. clinicaltrials.gov id : nct01513837
por: Castillo, José A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uooptf8c2tal9h57hq2v51819k